Medipostco
메디포스트 · 078160
Health Care Pharmaceuticals · KOSDAQ
Market cap US$322.7M (₩445.4B)
Overview
Medipostco makes stem-cell-based treatments for knee cartilage damage and operates a cord-blood banking service that stores newborns' umbilical-cord blood for potential future medical use.
Its products and services reach patients, hospitals, and families in South Korea, with subsidiaries advancing clinical trials in North America and Japan. Listed on KOSDAQ, Korea's tech and small-cap board, the company earns the largest share of its revenue from cord-blood banking, with its stem-cell therapy for knee osteoarthritis, marketed as Cartistem, as its second major revenue contributor. It also supplies health supplements under a separate consumer brand.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$49.7M
- FY2024US$51.2M
- FY2025US$53.4M
Operating profit
- FY2023−US$18.2M
- FY2024−US$35.2M
- FY2025−US$49.3M
Net income
- FY2023US$3.6M
- FY2024−US$45.9M
- FY2025−US$62.3M
Key ratios (FY2025)
Why it matters
Medipostco operates a dedicated contract development and manufacturing subsidiary, Medipostco CDMO, focused on cell and gene therapy manufacturing services.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?